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=	274)	 and	 cohort	 2	 was	 transplanted	 in	 1986-	2002	 (n	 =	352).	 Participants	 were	
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The	 virome	 component	 of	 the	 human	 microbiome	 is	 known	 to	
play an important role in disease,4,5	and	HPV	is	particularly	prevalent	
in	the	normal	skin	virome.6,7	HPVs	are	double-	stranded	DNA	viruses	
that	are	classified	 into	5	genera	 (α, β, γ, μ, and ν).8,9 αHPVs	 (eg,	mu-
cosal	HPV	types	16	and	18)	are	responsible	for	the	development	of	
cervical	carcinoma	and	other	mucosal	SCCs,	including	anogenital	and	
oropharyngeal carcinomas.10	The	 role	of	 skin	βPVs	 in	cSCC	carcino-
genesis is controversial,9,11,12	but	evidence	for	etiologic	 involvement	





viruses	as	part	of	their	normal	skin	virome.7,19,20 Hair follicles are the 




HPV	 infection	 and	 cSCC,12,20-24	 in	 particular,	 in	 OTRs.25,26	 In	 most	
studies,	HPV	infection	has	been	determined	by	detection	of	serologic	
responses to a large series of βPV	and	sometimes	γPV	types12,21–23,25–31 
and	less	frequently	by	detecting	genomic	DNA	from	1	or	multiple	HPV	
types	in	eyebrow	hair	or	skin	scrapings.20,21,25,32-34
Case-	control	 studies	 in	both	OTR	and	 immunocompetent	popu-




motes active proliferation of βPV.	To	our	best	knowledge,	there	is	only	
1	published	cohort	study	 in	OTRs	that	 investigated	the	 influence	of	
βPV	infection	on	the	development	of	cSCC.26	In	a	single-	center	study	
in	 445	 patients,	OTRs	who	were	 βPV	 seropositive	 around	 the	 time	
of	 transplantation	had	an	almost	3-	fold	 increased	risk	of	developing	







2.1 | Participants and study design
As	 part	 of	 a	 European	 Union–funded	 fifth	 framework	 program	
(5FP)	 collaborative	 research	 grant	 (QLK2-	CT-	2002-	0117),	 the	 EPI-	
HPV-	UV-	CA	 study	 group	 collected	 data	 for	 a	 prospective35 and a 




eyebrow	hair	 by	 using	 polymerase	 chain	 reaction–based	methods.	βPV	 IgG	 serore-
sponses	were	determined	with	multiplex	serology.	A	competing	risk	model	with	de-
layed	entry	was	used	to	estimate	cumulative	incidence	of	histologically	proven	cSCC	
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follow-	up	 data	 (n	 =	242),	 an	 cSCC	diagnosed	before	 recruitment	 (n	
=	210),	 or	 transplanted	 before	 1986	 (n	 =	111)	 gave	 a	 total	 of	 352	
OTRs.	Both	cohorts	were	under	prospective	observation	until	2016.
Between	2003	 and	2006,	 relevant	 demographic	 data	 and	 infor-
mation	 about	 skin	 cancer	 risk	 factors	were	 collected.3,25,35	 Plucked	
eyebrow	 hair	 was	 collected;	 DNA	was	 extracted	 for	 detection	 and	
genotyping	 of	 25	βPV	 types	 using	 the	 skin	βPV	prototype	 research	
assay	(Labo	Bio-	medical	Products	BV,	Rijswijk,	The	Netherlands)36 and 
for	viral	 load	determination	using	quantitative	polymerase	 chain	 re-
action.32	Because	more	than	95%	of	OTRs	had	1	or	more	βPV	types	
in	their	eyebrow	hair,25	we	dichotomized	the	number	of	βPV	as	0	to	
4	and	as	5	or	more,	as	previously	published.25 High viral load was de-























oncology	 databases	 to	 collect	 this	 information.	 Both	 cohort	 studies	
adhered	to	the	Declaration	of	Helsinki	principles,	and	the	local	medical	
ethical committees of the hospitals in the participating countries had 
approved the study design.
2.2 | Statistical analysis




The starting date for analysis was the day of transplantation; the end 
dates	 for	 those	 not	 diagnosed	with	 cSCC	 or	 BCC	were	 the	 end	 of	
follow-	up	 or	 death.	 Proportionality	 of	 the	 hazard	 was	 assessed	 by	
plotting	Schoenfeld	residuals	for	relevant	covariates	and	by	introduc-
ing	interactions	of	relevant	covariates	with	time	in	the	Cox	model.	A	
value of P <	.05	indicated	a	violation	of	the	proportionality	assumption.
A	competing	 risk	model	with	death	as	competing	event	and	de-
layed	entry	(also	referred	to	as	left	truncation)	was	used	to	estimate	
the	 cumulative	 incidence	 of	 first	 cSCC	 or	 BCC	 since	 transplanta-















ing differences in patient populations, immunosuppression regimens, 
and	sun	exposure	between	the	3	clinical	sites).	We	also	investigated	
the	other	clinical	variables,	and	none	changed	the	estimates	of	inter-
















respectively.	The	median	and	maximum	 follow-	up	 times	 since	DNA	
and	serum	sampling	did	not	differ	between	the	cohorts	and	were	9.8	






often	 female,	 had	 a	darker	 skin	 type,	were	 less	often	 smokers,	 and	
had	 lower	alcohol	 consumption.	Almost	all	 received	mycophenolate	
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TABLE  1 Baseline	characteristics	of	the	626	organ	transplant	recipients
Cohort 1 Cohort 2 Combined cohort
No. of patients 274 352 626
Years	of	first	transplantation 2003-	2006 1986-	2002 1986-	2006
Study	center,	n	(%)
Leiden	(The	Netherlands) 101	(36.9) 91	(25.9) 192	(30.7)
Lyon	(France) 99	(36.1) 64	(18.2) 163	(26.0)
London	(UK) 32	(11.7) 123	(34.9) 155	(24.8)
Bergamo	(Italy) 42	(15.3) 74	(21.0) 116	(18.5)
P < .001
Sex,	n	(%)
Women 98	(35.8) 96	(27.3) 194	(31.0)
Men 176	(64.2) 256	(72.7) 432	(69.0)
P = .023
Age	at	transplantation,	y
Median 56.4 50.3 52.4
IQR	(25%-	75%) 47.9-	62.6 38.4-	57.3 42.0-	58.9
P = .003
Age	at	physical	examination,	y
Median 56.4 59.8 58.2
IQR	(25%-	75%) 48.0-	62.6 52.7-	67.1 51.3-	65.7
P < .001
Skin	phototype,	n	(%)
Dark/olive 157	(57.5) 162	(46.0) 319	(51.1)
Medium 91	(33.3) 128	(36.4) 219	(35.0)
Fair 25	(9.2) 62	(17.6) 87	(13.9)
Missing values (1) P = .002
Type	of	organ,	n	(%)
Kidney 220	(80.3) 288	(81.9) 508	(81.2)
Kidney	and	pancreas 34	(12.4) 29	(8.2) 63	(10.0)
Heart 20	(7.3) 35	(9.9) 55	(8.8)
P	=	.140
Immunosuppressive	therapy,	n	(%)
Aza	in	any	combination 14	(5.1) 148	(42.0) 162	(25.9)
MMF	in	any	combination 251	(92.0) 108	(30.7) 359	(57.5)
CyA	or	Tac	without	Aza	or	MMF 8	(2.9) 96	(27.3) 104	(16.6)
Missing values (1) P < .001
Average	daily	sun	exposure,	n	(%)
1-	3	h 175	(63.9) 208	(59.1) 383	(61.2)
≥4	h 99	(36.1) 144	(40.9) 243	(38.8)
P	=	.224
Sunburns	before	the	age	of	20	y,	n	(%)
0 110	(40.4) 174	(49.4) 284	(45.5)
1-	4 108	(39.7) 123	(34.9) 231	(37.0)
≥5 54	(19.9) 55	(15.6) 109	(17.5)
Missing values (2) P	=	.073
(Continues)
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mofetil	 in	 combination	 with	 tacrolimus,	 rather	 than	 azathioprine,	
which was the main immunosuppressive drug in cohort 2. The num-
bers	of	keratotic	 lesions	and	common	viral	warts	were	higher	 in	co-
hort 2, consistent with their longer duration of immunosuppression 
(Table	1).
Table	2	 shows	 the	 cause-	specific	HRs	 for	 prognostic	 factors	 as-
sociated	 with	 cSCC	 in	 the	 2	 cohorts	 combined.	 Results	 generated	
from	 individual	 cohort	 analyses	 are	 comparable	 (Tables	 S1	 and	 S2).	
Male	sex,	increasing	age,	fair	skin	type,	and	immunosuppression	with	
azathioprine	were	 the	 strongest	 risk	 factors	 for	 cSCC.	 Because	 the	
Cohort 1 Cohort 2 Combined cohort
Smoking,	n	(%)
No 139	(50.8) 133	(38.1) 272	(43.7)
1-	19	pack-	y 76	(27.7) 136	(39.0) 212	(34.0)
≥20	pack-	y 59	(21.5) 80	(22.9) 139	(22.3)
Missing values (3) P = .003
Alcohol	consumption,	n	(%)
No 112	(57.1) 98	(27.8) 210	(38.3)
1-	19	g/d 64	(32.7) 188	(53.4) 252	(56.0)
≥20	g/d 20	(10.2) 66	(18.8) 86	(15.7)
Missing values (78) P < .001
Keratotic	skin	lesions,	n	(%)
0 205	(74.8) 111	(31.6) 316	(50.6)
1-	49 65	(23.7) 208	(59.3) 273	(43.6)
≥50 4	(1.5) 32	(9.1) 36	(5.8)
Missing values (1) P < .001
Common	viral	warts,	n	(%)
0 234	(85.7) 203	(57.8) 437	(70.0)
1-	49 33	(12.1) 103	(29.3) 136	(21.8)
≥50 6	(2.2) 45	(12.8) 51	(8.2)
Missing values (1) (1) P < .001
No. of βPV	types	in	hair
Median 4.5 4.0 4.0
IQR	(25%-	75%) 2.3-	6.8 2.0-	8.0 2.0-	7.0
P	=	.643
No. of βPV	types	in	hair
0-	4	 142	(51.8) 174	(49.4) 316	(50.5)
≥5 132	(48.2) 178	(50.6) 310	(49.5)
P	=	.552
βPV	load	(based	on	8	βPV	types)
Low	load	(1	copy	per	≥20	cells) 195	(71.2) 252	(71.6) 447	(71.4)
High	load	(1	copy	per	<20	cells) 79	(28.8) 100	(28.4) 179	(28.6)
P = .907
HPV	seropositivity
αPV 165	(60.2) 188	(53.4) 353	(56.4)
βPV 137	(50.0) 176	(50.0) 313	(50.0)
γPV 133	(48.5) 165	(46.9) 298	(47.6)
μPV 91	(33.2) 100	(28.4) 192	(30.5)
νPV 31	(11.3) 31	(8.8) 62	(9.9)
P	>	.05








Cause- specific univariate 
HR Adjusted HRaNo SCC SCC
No. of patients 536 90
Study	center,	n	(%)
Leiden	(The	Netherlands) 172	(32.1) 20	(22.3) 1 1
Lyon	(France) 144	(26.9) 19	(21.1) 1.4	(0.72-	2.6) 0.93	(0.49-	1.8)
London	(UK) 126	(23.5) 29	(32.2) 1.8	(0.99-	3.2) 1.6	(0.88-	2.9)
Bergamo	(Italy) 94	(17.5) 22	(24.4) 1.5	(0.83-	2.8) 1.7	(0.90-	3.1)
Sex,	n	(%)
Women 176	(32.8) 18	(20.0) 1 1
Men 360	(67.2) 72	(80.0) 1.7 (1.01-2.7) 2.0 (1.2-3.5)
Age	at	transplantation	per	10	y
Median 51.9 54.8
IQR	(25%-	75%) 41.9-	58.8 46.8-	61.8 1.8 (1.4-2.1) 2.1 (1.7-2.6)
Age	at	physical	examination	per	10	y
Median 57.8 64.5
IQR	(25%-	75%) 51.2-	65.43 58.1-	67.6 1.9 (1.5-2.3) 2.1 (1.7-2.7)
Skin	phototype,	n	(%)
Dark/olive 287	(53.6) 32	(35.6) 1 1
Medium 184	(34.4) 35	(38.9) 1.6	(0.99-	2.6) 1.9 (1.2-3.2)
Fair 64	(12.0) 23	(25.5) 3.3 (1.9-5.6) 3.9 (2.2-7.0)
Missing values (1)
Type	of	organ,	n	(%)
Kidney 434	(81.0) 74	(82.2) 1
Kidney	and	pancreas 59	(11.0) 4	(4.4) 0.45	(0.16-	1.2) 0.81	(0.28-	2.4)
Heart 43	(8.0) 12	(13.4) 1.8	(0.97-	3.3) 1.1	(0.53-	2.2)
Immunosuppressive	therapy,	n	(%)
Aza	in	any	combination 108	(20.2) 54	(60.0) 1 1
MMF	in	any	combination 334	(62.4) 25	(27.8) 0.22 (0.13-0.38) 0.28 (0.15-0.50)
CyA	or	Tac	without	Aza	or	MMF 93	(17.4) 11	(12.2) 0.33 (0.17-0.64) 0.25 (0.13-0.50)
Missing values (1)
Average	daily	sun	exposure,	n	(%)
1-	3	h 335	(62.5) 48	(53.3) 1 1
≥4	h 201	(37.5) 42	(46.7) 1.4	(0.90-	2.1) 1.1	(0.71-	1.7)
Sunburns	before	the	age	of	20	y,	n	(%)
0 243	(45.4) 41	(46.1) 1 1
1-	4 196	(36.7) 35	(39.3) 1.1	(0.68-	1.7) 0.91	(0.56-	1.	5)
≥5 96	(17.9) 13	(14.6) 0.92	(0.49-	1.7) 0.66	(0.33-	1.3)
Missing values (1) (1)
Smoking,	n	(%)
No 240	(44.9) 32	(36.0) 1 1
1-	19	pack-	y 182	(34.1) 30	(33.7) 1.1	(0.69-	1.9) 0.94	(0.56-	1.6)
≥20	pack-	y 112	(21.0) 27	(30.3) 1.9 (1.1-3.2) 1.1	(0.65-	1.9)
Missing values (2) (1)
(Continues)
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majority	 (>80%)	 of	 both	 cohorts	 were	 kidney	 transplant	 recipients,	








The	 number	 of	 βPV	 types	 in	 eyebrow	 hair,	 βPV	DNA	 load,	 and	
serologic	 responses	 to	HPV	did	not	 significantly	differ	between	 the	
2	cohorts	 (Table	1).	Figure	1	 shows	a	higher	overall	 cumulative	 inci-
dence	of	cSCC	 in	OTRs	 infected	with	multiple	 (≥5)	HPV	types	mea-
























Data	 on	 individual	HPV	 types	 suggested	 that	 βPV	 of	 species	 1,	
specifically	HPV	types	5,	8,	20,	21,	and	36,	are	those	most	likely	to	be	








that the diversity and load of infecting βPV	types	were	associated	with	
an	approximately	doubled	risk	of	cSCC.	Our	results	were	robust	after	
adjustment for multiple potential confounders. This level of increased 
risk	 is	equivalent	 to	 that	associated	with	other	well-	established	 risk	
factors	such	as	skin	phototype3 and points to an important role for the 
skin	virome	and	specifically	HPV	in	the	pathogenesis	of	cSCC.
HPV	 constitute	 an	 important	 part	 of	 the	 normal	 human	 skin	 vi-
rome.6,7,19,20	There	is	strong	evidence	from	laboratory	studies	to	suggest	
N (%)
Cause- specific univariate 
HR Adjusted HRaNo SCC SCC
Alcohol	consumption,	n	(%)
No 190	(41.0) 20	(23.5) 1 1
1-	19	g/d 207	(44.7) 45	(52.9) 1.6	(0.97-	2.8) 1.4	(0.83-	2.5)
≥20	g/d 66	(14.3) 20	(23.6) 2.5 (1.3-4.6) 1.8	(0.93-	3.5)
Missing values (73) (5)
Keratotic	skin	lesions,	n	(%)
0 299	(55.9) 17	(18.9) 1 1
1-	49 213	(39.8) 60	(66.7) 4.1 (2.3-7.1) 3.1 (1.7-5. 5)
≥50 23	(4.3) 13	(14.4) 8.0 (3.8-16.6) 4.7 (2.0-10.9)
Missing values (1)
Common	viral	warts,	n	(%)
0 387	(72.5) 50	(55.6) 1 1
1-	49 113	(21.1) 23	(25.6) 1.3	(0.80-	2.2) 1.3	(0.77-	2.2)

















































































































































































Patients at risk 1 year 5 year 10 year 15 year 20 year 25 year 30 year
0-4 HPV 156 166 130 86 66 22 0
5+ HPV 95 115 108 86 57 18 0
Patients at risk 1 year 5 year 10 year 15 year 20 year 25 year 30 year
Low load 190 209 171 127 92 29 0
High load 73 82 68 45 31 11 0
Patients at risk 1 year 5 year 10 year 15 year 20 year 25 year 30 year
Seronegative 132 148 116 82 62 20 0
Seropositive 131 144 123 91 61 20 0




Patients at risk 1 year 5 year 10 year 15 year 20 year 25 year 30 year
Seronegative 132 148 116 82 62 20 0
Seropos disconcordant 61 68 60 47 33 10 0
Seropos concordant 70 76 66 45 28 10 0
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that	HPV	plays	a	role	in	cSCC	carcinogenesis,	principally	through	syn-
ergy	with	UVR.13-15	In	normal	cells,	UVR	upregulates	cellular	defense	




infected	 cells	 that	 are	 highly	 susceptible	 to	 chromosomal	 instability	
and	malignant	transformation	by	UVR.9,15,43	Synergy	between	βPV	and	
UVR	has	also	been	documented	in	animal	models.	In	transgenic	mice	















infection	and	cSCC	 is	even	stronger,	 as	we	may	have	 failed	 to	detect	
additional	relevant	HPV	infections.	We	also	observed	that	seropositivity	
to γPV	was	associated	with	subsequent	cSCC,	supporting	recent	findings	
that γPV	type	HPV197	is	commonly	present	in	skin	tumors34 and that its 








of events during the first 10 years after transplantation. Therefore, 






planted, especially in Leiden and London.
Other	 potential	 limitations	 of	 this	 study	 are	missing	 data	 in	 the	
clinical	 characteristics	 included	 in	 the	 multivariable	 analyses.	 Of	
TABLE  3 Risk	of	cutaneous	squamous	cell	carcinoma	in	organ	transplant	recipients	with	human	papillomavirus	infection	according	to	the	
presence of βPV	DNA	and/or	serologic	response	to	βPV












univariate HR Adjusted HRc
Cause- specific 
univariate HR Adjusted HRc
βPV	DNA	(based	on	25	βPV	types)
0-	4	types 1 1 1 1 1
≥5 2.6	(0.82-	8.3) 1.8 (1.1-2.8) 1.6	(0.998-	2.7) 1.9 (1.2-2.9) 1.7 (1.1-2.6)
βPV	load	(based	on	8	βPV	types)
Low	load	(1	copy	per	≥20	cells) 1 1 1 1 1
High	load	(1	copy	per	<20	cells) 4.6 (1.5-13.8) 1.8 (1.1-2.8) 1.5	(0.92-	2.4) 2.1 (1.4-3.1) 1.8 (1.2-2.8)
βPV	serology	(based	on	16	βPV	types)
Seronegative 1 1 1 1 1
Seropositive 1.0	(0.36-	2.9) 1.6 (1.02-2.6) 1.5	(0.90-	2.4) 1.5	(0.97-	2.3) 1.4	(0.90-	2.1)
Combination	βPV	DNA	and	serology
Seronegative	irrespective	DNA 1 1 1 1 1
Seropositive	without	concordant	
DNA
0.98	(0.25-	3.9) 1.2	(0.69-	2.2) 1.2	(0.66-	2.2) 1.2	(0.69-	2.0) 1.2	(0.71-	2.1)
Seropositive	with	concordant	DNA 1.1	(0.31-	3.6) 2.0 (1.2-3.3) 1.7 (1.002-3.0) 1.8 (1.1-2.9) 1.5	(0.93-	2.5)
γPV	serology	(based	on	6	γPV	types)
Seronegative 1 1 1 1 1
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particular	concern	 is	 the	28%	missing	data	for	alcohol	consumption,	
but	we	found	no	evidence	that	adjusting	for	alcohol	in	those	with	com-
plete information made any difference to the estimates of association 
between	HPV	and	cSCC.	We	have	no	good	explanation	why	we	did	






This cohort study provides evidence that infection with βPV	 is	
associated	with	 the	development	of	cSCC.	βPV	vaccines	are	now	 in	
development, and our data provide a rationale for routine pretrans-
plantation	 screening	 of	 the	 skin	 virome	 for	 βPV	 content	 and	 βPV	
vaccination	 of	 high-	risk	 individuals	 as	 a	 possible	 future	 strategy	 for	
reducing	the	burden	of	posttransplantation	cSCC.
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